Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA4 | P22748 | 1/20 | 0.31 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.30 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.30 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6332429 | 0.78 | — | — | |
| Hydrochloric Acid SCHEMBL23581008 | 0.76 | — | — | |
| Hydrochloric Acid SCHEMBL691435 | 0.76 | — | — | |
| SCHEMBL1324159 | 0.73 | — | — | |
| SCHEMBL20812345 | 0.70 | — | — | |
| Acetic Acid SCHEMBL27615002 | 0.69 | GABRA5 (0.35) | CA1CA2CA4KMT2A | |
| SCHEMBL18085517 | 0.68 | CA1 (0.52) | CA1CA2CA4KMT2A | |
| SCHEMBL16204599 | 0.67 | — | — | |
| SCHEMBL16204606 | 0.67 | — | — | |
| SCHEMBL6899302 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1392657-A4 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2004-03-10 | — | — | EP | disclosed |
| EP-1392657-A2 | PROTEASE INHIBITORS | SmithKline Beecham Corporation (US) | 2004-03-03 | — | — | EP | disclosed |
| US-20040038965-A1 | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION | 2004-02-26 | — | — | US | disclosed |
| WO-2003053331-A2 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040038965-A1 | Protease inhibitors | CTSK, CTSZ, CTSE | CA1 136/4885CA2 94/4885CA4 77/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.